Pharmacies must pay $650.6 million to Ohio counties in opioid case

Pharmacies must pay 0.6 million to Ohio counties in opioid case


A customer views merchandise for sale at a Walgreens store in the Hollywood neighborhood of Los Angeles.

Christopher Lee | Bloomberg | Getty Images

Pharmacy operators CVS, Walmart and Walgreens must pay a combined $650.6 million to two Ohio counties to address the damage done by the opioid epidemic, a federal judge ruled on Wednesday.

The order by U.S. Judge Dan Polster in Cleveland comes after a jury last November concluded that the pharmacy chains helped create a public nuisance in Lake and Trumbull counties by over-supplying addictive pain pills, many of which found their way onto the black market. The pharmacies have said they would appeal that verdict.

Polster held a separate non-jury trial earlier this year to decide how much the companies had to pay.

“We are disappointed with this outcome,” Walgreens spokesman Fraser Engleman said in a statement. “The facts and the law did not support the jury verdict last fall, and they do not support the court’s decision now.”

CVS and Walmart did not immediately respond to requests for comment.

Polster said the sum must be paid over 15 years, with the amount for the first two years, or $86.7 million, to be paid into a fund immediately. The judge also ordered the companies to implement new procedures to combat illegal diversion of opioid drugs.

The U.S. opioid epidemic has caused more than 500,000 overdose deaths over two decades, according to government data. More than 3,300 opioid lawsuits have been filed nationally against drugmakers, distributors and pharmacy chains.

The litigation has resulted in several nationwide settlements, including a $26 billion deal with Johnson & Johnson and the three leading distributors, a $2.37 billion settlement with AbbVie Inc and a $4.25 billion settlement with Teva Pharmaceutical Industries Ltd.

Pharmacies have yet to reach a nationwide settlement.



Source

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
Health

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]

Read More
23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo
Health

23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023.  Jordan Vonderhaar | Bloomberg | Getty Images All seven independent directors of 23andMe resigned from the company’s board Tuesday, a move that CEO Anne Wojcicki said left her “surprised […]

Read More
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Health

Healthy Returns: How competitive can Roche be in the weight loss drug market?

Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.  Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]

Read More